VYNE
VYNE
NASDAQ · Pharmaceuticals

Vyne Therapeutics Inc

$28.30
-0.99 (-3.38%)
As of Sep 22, 5:21 PM ET ·
Financial Highlights (FY 2026)
Revenue
2.04M
Net Income
-94,661,469
Gross Margin
Profit Margin
-4,646.1%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 93.4% 36.5% 36.5%
Operating Margin -5,219.1% -4,697.2% 24.1% 26.2%
Profit Margin -4,646.1% -4,413.8% 22.3% 17.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 2.04M 28.2K 2.72M 3.05M
Gross Profit 26.3K 990.9K 1.11M
Operating Income -106,337,795 -1,324,709 655.4K 797.6K
Net Income -94,661,469 -1,181,711 604.8K 522.0K
Gross Margin 93.4% 36.5% 36.5%
Operating Margin -5,219.1% -4,697.2% 24.1% 26.2%
Profit Margin -4,646.1% -4,413.8% 22.3% 17.1%
Rev Growth +5.9% -5.6% +23.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 5.81M 7.24M
Total Equity 10.77M 11.64M
D/E Ratio 0.54 0.62
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -106,253,381 -1,400,261 831.2K 1.01M
Free Cash Flow 485.0K 536.6K